Etoricoxib is safe and effective in preventing heterotopic ossification after primary total hip arthroplasty

Table 3 Follow-up data 1 year postop

Follow-up PAO	Preop	Follow-up at least 1 year postop.
Included	194
Deaths	0	3 (E)
Excluded because of early stop of PAO prophylaxis	0	4 (D, see above)
Excluded because of joint dislocation or revision surgery	0	7 (F)
Expected	194	180 (G)
Actual complete examination including radiographs	194	143 (H) (79.4%)
Clinical examination but no radiographs at follow-up	0	14 (I) (7.8%)
Only contact by phone	0	22 (J) (12.2%)
Not available	0	1 (K)

(E) All three patients died more than 6 months after surgery because of carcinoma already known preoperatively (pharynx, prostate, breast); death was unrelated to surgery or PAO prophylaxis. (F) One patient suffered dislocation of the hip 4 months postoperatively (closed reposition of the hip). Revision surgery was performed in five patients: Two periprosthetic infections (diagnosed 19 respectively 28 days postoperatively) with two stage implant exchange, two wound healing disorders without proof of germs, one cup dislocation with component exchange 11 months postoperatively. One revision surgery because of traumatic periprosthetic fracture 9 months postoperatively. (G) Expected = Included minus deaths, minus excluded for early stop of PAO prophylaxis, minus joint dislocation or revision surgery. (H) Actual complete examination including radiographs at follow-up = maximum number of subjects for data analysis concerning periarticular ossification (=100%). (I) Patients did not agree to any x-ray control; everyone was satisfied with the result of the operation. (J) Patients were not ready for a follow-up visit (reduced mobility due to age, great distance to the hospital, said they had no time); everyone was satisfied with the result of the operation. (K) Patient moved to unknown location

ISSN: 1749-799X